Vicore to host webcast with updated AIR trial results after presentation at the ATS congress

• Webcast to be held on: May 26, 2023 at 08:00 EST/14:00 CET

Stockholm, May 17, 2023 – Vicore Pharma Holding AB (STO:VICO) (“Vicore”), unlocking the potential of a new class of drugs to stop disease progression and restore function, will hold a webcast including a Q&A session to present interim results from the phase 2a trial AIR, which evaluates treatment with C21 in patients with idiopathic pulmonary fibrosis (IPF), on May 26 2023 at 08:00 EST/14:00 CET. C21 is a first-in-class orally administered angiotensin II type 2 receptor agonist (ATRAG) in development for the treatment of IPF.

Professor Toby Maher, from Keck School of Medicine at University of Southern California, will present data along with Carl-Johan Dalsgaard, CEO, and Rohit Batta, CMO of Vicore. The webcast will provide an updated interim analysis based on a more advanced dataset, encompassing a comprehensive examination of the patient population and biomarkers. Additionally, the discussion will cover the future steps for the AIR trial and development plans to ensure widespread availability of C21 for patients requiring it.

Webcast details
C21 in IPF – Presentation of an advanced interim analysis
Date and time: Friday May 26, 2023 at 08:00 EST/14:00 CET 
How to join: https://stream.brrmedia.co.uk/broadcast/645cb5017935152b5ae742f1
The webcast will be available for playback after the event on: https://vicorepharma.com/investors/events-presentations/

Carl-Johan Dalsgaard, CEO of Vicore, commented: “I am pleased to offer an opportunity for people not present during the ATS congress, to review and discuss the data from the new interim analysis and the potential of C21 in treating IPF.”

About the AIR presentation during the ATS congress
Professor Toby Maher, Keck School of Medicine at University of Southern California, will present the AIR interim results of the phase 2a AIR trial in idiopathic pulmonary fibrosis (IPF) during the American Thoracic Society (ATS) International Conference in Washington DC on May 21. The results presented will come from a larger and more advanced data set than previously reported. It will also include a thorough analysis of the patient population.

About the phase 2a AIR trial in IPF (idiopathic pulmonary fibrosis)
The purpose of this exploratory trial is to investigate the safety and efficacy of C21 in treatment-naïve patients with IPF. The trial is an open-label, single-arm trial in which C21 is administered orally twice daily as monotherapy for 24 weeks with an option to continue treatment for another 12 weeks. Patients with IPF have a well-characterized decline in lung function. The effect of C21 on lung function, measured as change in Forced Vital Capacity (FVC) from baseline, is investigated. The trial involves multiple centers with regulatory approvals obtained in the UK, India, Ukraine and Russia. The trial is paused in Ukraine and Russia due to the ongoing conflict. In November 2022, Vicore presented an interim analysis of 41 patients, further confirming earlier results with a stabilization of lung capacity already at week 6 and, a subsequent increase of lung function from weeks 18 to 36. The increase was more pronounced in IPF patients without end-stage destruction of lung parenchyma as documented by high resolution computer tomography (HRCT). 

For further information, please contact:

Vicore
Carl-Johan Dalsgaard, CEO
Tel: +46 70 975 98 63
carl-johan.dalsgaard@vicorepharma.com  

Optimum Strategic Communications
Mary Clark, Hana Malik, Katie Flint
Tel: +44 20 3882 2119
vicore@optimumcomms.com

This information was submitted for publication on May 17 at 08:00 CET.

About Vicore Pharma Holding AB (publ)
Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life- changing treatments in diseases where the AT2 (angiotensin II type 2) receptor has a central role in stopping and reversing disease pathology. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG). Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. With our unique expertise in the ATRAG biology we fuel our pipeline with several new assets with long patent life for a variety of diseases, some of which could be partnered while others can be taken to the market by Vicore.
The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.